Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

ClinicalTrials.gov ID: NCT00370331

Public ClinicalTrials.gov record NCT00370331. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy, Safety and Tolerability of Eltrombopag Olamine (SB-497115-GR), a Thrombopoietin Receptor Agonist, Administered for 6 Months as Oral Tablets Once Daily in Adult Subjects With Previously Treated Chronic ITP.

Study identification

NCT ID
NCT00370331
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
197 participants

Conditions and interventions

Interventions

  • eltrombopag Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2006
Primary completion
Jun 30, 2008
Completion
Jun 30, 2008
Last update posted
Apr 17, 2017

2006 – 2008

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
23
Facility City State ZIP Site status
GSK Investigational Site Duarte California 91010
GSK Investigational Site Los Angeles California 90033
GSK Investigational Site San Francisco California 94143
GSK Investigational Site Washington D.C. District of Columbia 20007
GSK Investigational Site Washington D.C. District of Columbia 20010-2975
GSK Investigational Site Hollywood Florida 33021
GSK Investigational Site Atlanta Georgia 30341
GSK Investigational Site Savannah Georgia 31405
GSK Investigational Site Honolulu Hawaii 96813
GSK Investigational Site Boston Massachusetts 02114
GSK Investigational Site Worcester Massachusetts 01655
GSK Investigational Site St Louis Missouri 63110
GSK Investigational Site Buffalo New York 14215
GSK Investigational Site New York New York 10029
GSK Investigational Site New York New York 10065
GSK Investigational Site Cleveland Ohio 44106
GSK Investigational Site Lawton Oklahoma 73505
GSK Investigational Site Portland Oregon 97227
GSK Investigational Site Willow Grove Pennsylvania 19090
GSK Investigational Site Dallas Texas 75137
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Lubbock Texas 79410
GSK Investigational Site Lubbock Texas 79415
GSK Investigational Site Arlington Virginia 22205
GSK Investigational Site Seattle Washington 98109
GSK Investigational Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00370331, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 17, 2017 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00370331 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →